Get 40% Off
🎁 Free Gift Friday: Copy Legendary Investors' Portfolios in One ClickCopy for Free

Perrigo's Stock Up, Starboard's CEO Calls It A Key Pick

Published 09/12/2017, 11:29 PM
Updated 07/09/2023, 06:31 AM

Perrigo Company plc’s (NYSE:PRGO) shares increased almost 5% after Jeff Smith, CEO of Starboard Value, a New York-based investment consulting company, declared that the company was a top investment option at the Delivering Alpha event hosted by CNBC.

Notably, Perrigo is one of the world’s largest manufacturers of over-the-counter (OTC) healthcare products and supplier of infant formulas for the store brand market. It is a leading provider of branded OTC products in the EU and the United States. The company also produces generic standard topical products.

However, Perrigo’s shares have underperformed the industry so far this year. The stock has gained 7% compared with the broader industry’s 21.7% increase.

During the conference, Jeff stated that Perrigo is undervalued at present due to pricing pressure, particularly in generics segment and because of changing dynamics in the United States. He continued to say that the company holds huge potential as a much larger business on the whole when compared with any single brand.

He further added that though many retailers are facing online challenges from e-commerce giants like Amazon (NASDAQ:AMZN) , Perrigo can utilize it as a prime distribution outlet for generic drugs and other over-the-counter (OTC) products.

At the conference, Jeff Smith also cited Altaba Inc. (NASDAQ:AABA) , a New York based investment company as another good option for investors to put money in.

We remind investors that Jeff Smith has placed a total of five members on the company’s board including two new ones who came late in 2016.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Rank & Stock to Consider

Perrigo currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ACADIA’s loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



Amazon.com, Inc. (AMZN): Free Stock Analysis Report

Perrigo Company (PRGO): Free Stock Analysis Report

ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.